Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Gains from Investment Securities (2023 - 2025)

Beta Bionics' Gains from Investment Securities history spans 2 years, with the latest figure at -$11.2 million for Q3 2025.

  • For Q3 2025, Gains from Investment Securities fell 32002.86% year-over-year to -$11.2 million; the TTM value through Dec 2025 reached -$11.2 million, down 48526.09%, while the annual FY2025 figure was $1.3 million, 77.34% down from the prior year.
  • Gains from Investment Securities for Q3 2025 was -$11.2 million at Beta Bionics, down from $8.2 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $8.2 million in Q1 2025 and bottomed at -$11.2 million in Q3 2025.